CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Rozpoznanie chłoniaka nieziarniczego, który wrócił po wcześniejszym leczeniu lub nie poddawał się mu
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Chętna, świadoma zgoda na udział w badaniu
- •Wcześniejsze leczenie co najmniej dwoma metodami terapeutycznymi
- •Diagnoza potwierdzona badaniem histologicznym lub cytologicznym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Massachusetts General Hospital
Boston, United States
Trial contact
Matthew Frigault, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.